A Phase I, Open-Label, Dose-Escalation Study to Investigate the Safety of ISTH0036, a 'Next Generation' TGF-β2-Selective Antisense Oligonucleotide, in Subjects With Primary Open-Angle Glaucoma Undergoing Trabeculectomy

Trial Profile

A Phase I, Open-Label, Dose-Escalation Study to Investigate the Safety of ISTH0036, a 'Next Generation' TGF-β2-Selective Antisense Oligonucleotide, in Subjects With Primary Open-Angle Glaucoma Undergoing Trabeculectomy

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 May 2017

At a glance

  • Drugs ISTH 0036 (Primary)
  • Indications Open-angle glaucoma
  • Focus Adverse reactions; First in man
  • Sponsors Isarna Therapeutics
  • Most Recent Events

    • 15 May 2017 Results from this trial published in an Isarna Therapeutics Media Release.
    • 15 May 2017 According to an Isarna Therapeutics media release, data from this trial were presented at The Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO).
    • 05 Sep 2016 Planned End Date changed from 1 Apr 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top